Granules India Q2 FY27 Results: Profit Jumps 39% and the FDA Inspection at Gagillapur Draws Attention

A milestone for Granules India (NSE: GRANULES): quarterly sales went above ₹1,500 crore for the first time, and profit grew by more than a third. Cash has overtaken debt on the balance sheet too, a switch from the net debt of June. Hyderabad is the other half of the story, where a US FDA team recently finished inspecting the Gagillapur plant and left a list of observations the company is working through.

Granules India Q2 FY27 Results: Revenue Up 20%, Profit After Tax Up 39%

The September quarter's sales number was ₹1,560 crore, a fifth better than a year ago and slightly above June. EBITDA reached ₹338 crore. Net profit was ₹182 crore, where last year it was ₹131 crore, and before tax the gain was 38%.

Profit as a share of sales improved too, from 10.1% to 11.7%. June's quarter was almost identical on profit, though costs for raw materials and shipping ate into the margin. Management blames the conflict in West Asia, and the gross margin of 64.4% sat 134 basis points under last year.

Gross margin fell, yet the EBITDA margin still edged up on last year. That means operating costs grew more slowly than sales, which is how a company can lose a little at the gross level and still report a better profit margin. That makes eight straight quarters of sales growth from one to the next.

Add up the two quarters and you get about ₹3,037 crore of sales and ₹362 crore of profit. The latest quarter sold more than the one before it but earned almost exactly the same, which says earnings are steady more than they are accelerating.

Granules India Sales Mix by Product and Region, Including Peptides

Finished dosages remain the core. The mix for the quarter looked like this:

· Finished dosages made up 73% of sales, active pharmaceutical ingredients 13%, and the intermediates used in formulations 10%.

· Peptide contract manufacturing is the newest line at 3% of sales. It still loses money at the operating level, about ₹15 crore this quarter against roughly ₹12 crore in June. The Swiss unit behind it, Senn Tides, came with the Senn Chemicals deal in April 2025 and has passed its GMP inspections in Zurich.

North America is still where most of the money comes from, although its share has slipped from 76% to 72% over the year. Sales there grew 14%. Europe has been the fastest-moving region, up 65% and now 16% of the total, and the rest of the world grew 17%. The company says it is also looking at Brazil and Mexico for products it already sells. Spreading sales across more regions sits on management's stated priority list, next to controlled substances, complex generics, oncology and peptides.

Granules India Cash Position: Net Cash of ₹828 Crore After the Warrant Money

The balance sheet changed direction in the quarter. At the end of June the company carried net debt of about ₹101 crore. By September it held net cash of ₹828 crore, helped by the final instalment of money from warrants.

Cash from operations was much weaker, at roughly ₹65 crore against about ₹387 crore in the June quarter. The company says it chose to put more money into working capital to support growth. Profit and cash flow were far apart this time, which is why the figure stands out.

Gagillapur FDA Inspection: What the Form 483 Means for Granules India

The US Food and Drug Administration inspected the Gagillapur finished-dosage plant from 19 to 30 October. It closed with a Form 483 listing eleven observations. Management says none relate to data integrity, cross-contamination or upkeep of the facility, and it expects to send a full response within 15 business days.

The site has been under a Warning Letter since February 2025, which is why the inspection matters more than the usual routine visit. The chairman has described the worst case as the existing Warning Letter staying in place. The FDA has not yet replied, so the outcome is open.

US Pipeline and Launches: First-to-File Filings and Controlled Substances

In the first half the company filed two more generic applications that could earn first-to-file status, which makes three in all. They are for amphetamine, sodium oxybate and ruxolitinib, each in extended-release form. Five US launches are lined up for the coming two quarters, and Granules holds third place in US controlled substances.

Peptide manufacturing for other drug makers is the longer bet. The chairman has said the unit could pass CHF 100 million in revenue within three to four years, and it serves innovator companies rather than the weight-loss drug market.

Granules India Share Price and Valuation Snapshot

The stock has spent the past year between ₹520 and ₹924, well above its low but short of its peak. Promoters own about 37%, foreign funds 20% and domestic institutions 15%, and the dividend yield is a small 0.22%.

Granules India Developments to Track After the Q2 Results

· The company's reply to the FDA on the eleven observations, and any word from the agency afterwards.

· Whether operating cash flow recovers from its weak September quarter.

· The pace of the five US launches planned for the next two quarters.

· Any approvals or filings on the three first-to-file applications.

· Input and logistics costs, which pulled the gross margin down this quarter.

· Whether the peptide unit gets closer to breaking even, as its operating loss widened a little from June to September.

Put simply, the numbers for the quarter were strong and the balance sheet got stronger. What the plant inspection leads to is the part the company cannot yet answer, and the next few weeks of correspondence with the regulator will decide how much attention it deserves.

Disclaimer: This article is analytical commentary for informational purposes and is not personalised investment advice.